Site search

Clear filter
2902 results for '' found
Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (NCT05618028)
Study M23-324: A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies (NCT05618028)
/
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection (NCT04903626)
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection (NCT04903626)
/
A Type II Hybrid Effectiveness-Implementation, Randomised Control Trial of Left Write Hook for Adult Survivors of Child Sexual Abuse (ACTRN12624000862549)
A Type II Hybrid Effectiveness-Implementation, Randomised Control Trial of Left Write Hook for Adult Survivors of Child Sexual Abuse (ACTRN12624000862549)
/
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
/
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who
/
IDENTIFYING IMMUNE AND INFECTIOUS BIOMARKERS OF EARLY AND LATE ALLOGRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANTATION (Trial Not Registered)
/
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
LuMIERE: A Phase 1/2 Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participa
/
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations (LOXO-IDH-20001) (NCT04603001)
/
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/
/
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemi
/
35 36 37 38 39